Associations - Opdivo (nivolumab)

TMB-H	Melanoma	TMB-H	Melanoma	nivolumab Sensitive: B - Late Trials ASCO 2023 - 1 week (New B) nivolumab Sensitive : B ASCO 2023 - 1wk	nivolumab Sensitive: B - Late Trials ASCO 2023 - 1 week nivolumab Sensitive : B ASCO 2023 - 1 week - (New B)
IL6 elevation	Melanoma	IL6 elevation	Melanoma	nivolumab + ipilimumab Resistant: B - Late Trials ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Resistant : B ASCO 2023 - 1wk	nivolumab + ipilimumab Resistant: B - Late Trials ASCO 2023 - 1 week nivolumab + ipilimumab Resistant : B ASCO 2023 - 1 week - (New C3)
High IFNG gene signature	Melanoma	High IFNG gene signature	Melanoma	nivolumab Sensitive: B - Late Trials ASCO 2023 - 1 week (New B) nivolumab Sensitive : B ASCO 2023 - 1wk	nivolumab Sensitive: B - Late Trials ASCO 2023 - 1 week nivolumab Sensitive : B ASCO 2023 - 1 week - (New B)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Sensitive : A1 ASCO 2023 - 1wk	nivolumab + ipilimumab Sensitive: A1 - Approval ASCO 2023 - 1 week nivolumab + ipilimumab Sensitive : A1 ASCO 2023 - 1 week - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	nivolumab Sensitive: B - Late Trials Bristol-Myers Squibb Press Release - 1 week (New B) nivolumab Sensitive : B Bristol-Myers Squibb Press Release - 1wk	nivolumab Sensitive: B - Late Trials Bristol-Myers Squibb Press Release - 1 week nivolumab Sensitive : B Bristol-Myers Squibb Press Release - 1 week - (New B)
BRAF mutation	Melanoma	BRAF mutation	Melanoma	nivolumab + ipilimumab Sensitive: B - Late Trials ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Sensitive : B ASCO 2023 - 1wk	nivolumab + ipilimumab Sensitive: B - Late Trials ASCO 2023 - 1 week nivolumab + ipilimumab Sensitive : B ASCO 2023 - 1 week - (New C3)
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	nivolumab Sensitive: C1 - Off-label ASCO 2023 - 1 week (New C3) nivolumab Sensitive : C1 ASCO 2023 - 1wk	nivolumab Sensitive: C1 - Off-label ASCO 2023 - 1 week nivolumab Sensitive : C1 ASCO 2023 - 1 week - (New C3)
MSI-H/dMMR	Gastric Cancer	MSI-H/dMMR	Gastric Cancer	nivolumab Sensitive: C1 - Off-label ASCO 2023 - 1 week (New C3) nivolumab Sensitive : C1 ASCO 2023 - 1wk	nivolumab Sensitive: C1 - Off-label ASCO 2023 - 1 week nivolumab Sensitive : C1 ASCO 2023 - 1 week - (New C3)
PD-L1 expression	Hepatocellular Cancer	PD-L1 expression	Hepatocellular Cancer	nivolumab Sensitive: C1 - Off-label ASCO 2023 - 1 week (New C3) nivolumab Sensitive : C1 ASCO 2023 - 1wk	nivolumab Sensitive: C1 - Off-label ASCO 2023 - 1 week nivolumab Sensitive : C1 ASCO 2023 - 1 week - (New C3)
IDH2 mutation + TMB-L	Glioma	IDH2 mutation + TMB-L	Glioma	nivolumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab Sensitive : C3 ASCO 2023 - 1wk	nivolumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week nivolumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
IDH1 mutation + TMB-L	Glioma	IDH1 mutation + TMB-L	Glioma	nivolumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab Sensitive : C3 ASCO 2023 - 1wk	nivolumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week nivolumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
PMS2 mutation + MLH1 mutation	Gastric Cancer	PMS2 mutation + MLH1 mutation	Gastric Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
PMS2 mutation + MLH1 mutation	Colorectal Cancer	PMS2 mutation + MLH1 mutation	Colorectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
HER-2 expression	Solid Tumor	HER-2 expression	Solid Tumor	nivolumab + BDC-1001 Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab + BDC-1001 Sensitive : C3 ASCO 2023 - 1wk	nivolumab + BDC-1001 Sensitive: C3 – Early Trials ASCO 2023 - 1 week nivolumab + BDC-1001 Sensitive : C3 ASCO 2023 - 1 week - (New C3)
MSH2 deletion + MSH6 deletion	Rectal Cancer	MSH2 deletion + MSH6 deletion	Rectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
MLH1 deletion+ PMS2 deletion	Rectal Cancer	MLH1 deletion+ PMS2 deletion	Rectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
MSH2 mutation	Rectal Cancer	MSH2 mutation	Rectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
MSH6 mutation	Rectal Cancer	MSH6 mutation	Rectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
KRAS wild-type	Non Small Cell Lung Cancer	KRAS wild-type	Non Small Cell Lung Cancer	nivolumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab Sensitive : C3 ASCO 2023 - 1wk	nivolumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week nivolumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
CTNNB1 mutation	Hepatocellular Cancer	CTNNB1 mutation	Hepatocellular Cancer	nivolumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab Sensitive : C3 ASCO 2023 - 1wk	nivolumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week nivolumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
TP53 mutation	Hepatocellular Cancer	TP53 mutation	Hepatocellular Cancer	nivolumab Resistant: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab Resistant : C3 ASCO 2023 - 1wk	nivolumab Resistant: C3 – Early Trials ASCO 2023 - 1 week nivolumab Resistant : C3 ASCO 2023 - 1 week - (New C3)
KDM1A expression	Small Cell Lung Cancer	KDM1A expression	Small Cell Lung Cancer	nivolumab + ipilimumab Resistant: C3 – Early Trials J Thorac Oncol - 2 weeks (New C3) nivolumab + ipilimumab Resistant : C3 J Thorac Oncol - 2wk	nivolumab + ipilimumab Resistant: C3 – Early Trials J Thorac Oncol - 2 weeks nivolumab + ipilimumab Resistant : C3 J Thorac Oncol - 2 weeks - (New C3)
KDM1A expression	Small Cell Lung Cancer	KDM1A expression	Small Cell Lung Cancer	nivolumab Resistant: C3 – Early Trials J Thorac Oncol - 2 weeks (New C3) nivolumab Resistant : C3 J Thorac Oncol - 2wk	nivolumab Resistant: C3 – Early Trials J Thorac Oncol - 2 weeks nivolumab Resistant : C3 J Thorac Oncol - 2 weeks - (New C3)
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + ipilimumab + cabozantinib tablet Sensitive: B - Late Trials N Engl J Med - 3 weeks (New B) nivolumab + ipilimumab + cabozantinib tablet Sensitive : B N Engl J Med - 3wk	nivolumab + ipilimumab + cabozantinib tablet Sensitive: B - Late Trials N Engl J Med - 3 weeks nivolumab + ipilimumab + cabozantinib tablet Sensitive : B N Engl J Med - 3 weeks - (New B)
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
HER-2 negative + PD-L1 expression	Gastric Cancer	HER-2 negative + PD-L1 expression	Gastric Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
LDH elevation	Melanoma	LDH elevation	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
ALK mutation	Lung Non-Squamous Non-Small Cell Cancer	ALK mutation	Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
BRAF V600 wild-type	Melanoma	BRAF V600 wild-type	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1

Opdivo (nivolumab)

Associations
(560)

Associations
(560)

Opdivo (nivolumab)

Associations(560)

Associations(560)

Associations
(560)

Associations
(560)